Rapid Molecular Diagnostics INC

7 years of research has led to the creation of a generic diagnostic chip that can be outfitted with a variety of capture molecules to detect different viruses, bacteria, antibiotic resistance, fungi, protiens, and toxicology. This chip is utulized by an ellipsometer which allows for unprecedented speed and sensitivity at an unprecedented cost.


Our Advantages

The RMD tests have the following advantages:
  • Extremely Fast Analysis of Test Site: less than ~5 seconds

  • Extremely Sensitive: Sub Angstrom measurements

  • Cost Effective: Sample and Reagents less than ~$10-20 a per Test

  • Adaptability: Able to make tests across the diagnostic market for current and future needs without changing the underlying technology

  • Flexibility: Swap the nanochip, Swap the tests. You do not need a new 30k instrument


Product Pipe Line

Back to Top

RMD is in the process of making:

Strangles test for veterinary medicine

Helps prescribe correct antibiotics to horses which are treated for rhodococcus by symptom due to it's severity

Allows non-infected horses to be removed from quarantine

Allows for test results in a timely and cost effective manner

Bacterial identification panel with resistance and suseptibility

Allows for inital sepsis bundle of care to contain narrow spectrum antibiotics by running a test at triage

Allows for correct antibiotics to be administered assisting in antibiotic stewardship

Allows for reduction in complications and further progression of disease by correct timely treatment

Reduction in overall hospital stay and ICU admissions for SIRs

Toxicology test for pain management

Allows for reduced time for toxicology screen to come back so that patients can recieve perscriptions sooner

Allows for pain management clinics to run their own diagnostics achieving true Point of Care service


Our Technology

Back to Top

RMD technology is dramatically different from other diagnostic technology by changing the fundemental detection and capture systems that are time consuming. In addition, due to wafer level manufacturing, the cost of production reduces the cost to the consumer significantly.

Generic Nanosensor

Generic nanosensor allows for unparrelled flexibility and adaptability for the capture layer creating a true platform

Ultra flat nanotechnology allows for heightened sensitivity when read by an ellipsometer

Wafer Level manufacturing of 1000s of tests at once allows for a cheap consumable

Ellipsometer

A well known semiconductor instrument capable of measuring sub angstrom film thickness variations

Can measure a test site in 50 miliseconds to 5 seconds

Combined system

Allows for rapid diagnostics to be performed

Allows for high sensitivity tests to be performed

Allows for cheap tests to be performed

Allows for multiple different types of tests to be performed without new instrumentation

The technology is protected by the patent "Sensor Device for Biosensing and Other Applications" US 2020/0348289 A1 owned by co-founders. All 18 claims were awarded in march 2022 and the patent will be finalized by the end of 2022.


About US

Back to Top

Rapid Molecular Diagnostics is a new company, but it springs from two very innovative companies and one remarkable physician.

Biological Mimetics, Inc. This remarkable company has developed:

  • Bioinformatics-based probe design
  • DNA-RNA hybridization conditions
  • Rational antigen design methods for deriving broadly protective vaccines
  • Two clinical stage spin-off companies.
    • Lantern Pharma, Inc. which is developing cancer therapeutics using AI-based precision medicine algorithms.
    • Keystone Bio, Inc. which is developing antibody treatments and preventatives for Alzheimer's and cardiac diseases.
Zyvex Labs This nanotechnology company has developed:
  • Atomically precise fabrication equipment used in Quantum Research for fabricating solid state devices,
  • An artificial retina for which a joint venture company has started human clinical trials in Europe
  • A spin-off company that has two Early feasibility studies approved for neuromodulation implants
Gerhard Maale MD Has innovated medical treatments, devices, and methods in:
  • Orthopedic Oncology, Pathology, Complex Total Joint Reconstructions, and Musculoskeletal Infections
  • Bioengineering for Upper and Lower Extremity Total Joint Revisions
  • Molecular Diagnostics
  • DNA and RNA Biochemistry - Gene Cancer Detections
  • Microbiology and Virology
  • Local Molecular Biodegradable Carriers for Antibiotics and Cancer Drugs
  • Biofilm Engineering

Rapid Molecular Diagnostic Founders:

     
Matthew Maale
Matthew, MS, is the Director of Research and Development at RMD. Mr. Maale has been the driving force behind the development of the ellipsometry-based diagnostic assays. Matthew has designed and developed the diagnostic nanosensor, partially optimized the production of ultra-flat surface films, partially optimized hybridization conditions, developed analytical models on the ellipsometer to assess thickness and refractive index, and generated preliminary data with CoV-2 probes and RNA.

Matthew received his B.S. in Mechanical Engineering from Texas Tech University in December, 2016 and recieved his Masters in 2020 from UTD in Biomedical Engineering.


Taralyn, MS, RMD's Director of Market Research has utilized her background in molecular immunology into the discovery market analysis for the identification and utilization of novel technologies. She is highly organized and assists in detailed product planning, scheduling, maintaining timelines, preparing reports, communicating between team members, and other important tasks. She has formally assisted in the preparation of information materials and website content, and in vetting potential GxP contract labs.

Taralyn received her B.S. in Biology from James Madison University in 2010, and Masters in Biotechnology from Mount Saint Marys University in 2016.

     
Taralyn Wiggins
     
Dr. Greg Tobin
Dr. Tobin, RMD's CEO, has led research and technical programs at BMI since 1999. Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; personnel management; coordination of multi-site studies and development of research facilities. Dr. Tobin fosters a highly interactive research and development group to apply the Company's proprietary technology, Immune Refocusing Technology, to the design of antigens that induce broader protection against heterologous challenge. Dr. Tobin continues to maintain research projects and interests in the development of broadened vaccines against human rhinovirus, RSV, poliovirus, influenza virus, HIV-1, and Acinetobacter baumannii. Dr. Tobin is currently the Principal Investigator on two active NIH SBIR grants and one STTR contract at DTRA.

Prior to joining BMI, Dr. Tobin was a Senior Scientist and Group Leader (Gene Expression Regulation Group) for SAIC-Frederick at the National Cancer Institute. While at the NCI, Dr. Tobin led projects related to development of virus-like particle (VLP) based vaccines for HIV-1, optimization of recombinant protein expression, development of animal models for AIDS and cancer, and investigations into the pathobiology and molecular mechanisms of bovine immunodeficiency virus (BIV) and visna virus. Dr. Tobin was a post-doctoral scientist applying transgenic mouse models to the understanding of oncogenesis in the laboratory of Dr. Terry Van Dyke. During his doctoral research, Dr. Tobin studied the replication of poliovirus with Dr. J. Bert Flanegan at the University of Florida. Prior to graduate studies, Dr. Tobin gained valuable insight into virology and research methods in the University of Virginia laboratory of Dr. Jay C. Brown and William W. Newcomb.


Rahul, RMD's VP of Engineering, joined Zyvex in 2001 to work on scaling down macro and meso size devices using MEMS and assembly. In this endeavor, Rahul has been PI on four DARPA programs to build the world's smallest electron column, the World's smallest ion microcolumn, the system integrator for a brain stimulation and recording instrument, and the developer of an implant for acute sensing during the critical phase of spinal cord injuries respectively. He is also the Director of MEMS, Nano Retina Inc and the system architect for Bionic Eye-NR600, an innovation to heal the blind. Rahul has over 25 published articles and more than 10 patents awarded/pending in his name. He is currently working on next generation Class III compliant neural transducers and, as adjunct faculty at University of Texas at Arlington, he has taught advanced Graduate level courses in MEMS and MEMS design.

In August 2018, Rahul Saini was awarded the Tech Titans Technology Inventors award.This award recognizes the pioneering accomplishments of a person, team or group responsible for the creation of breakthrough ideas, processes or products which have advanced the discipline(s) of the arts, education, electronics, energy, engineering, environment, medicine, and/or science. He was primarily recognized for his work on the NR-600 bionic eye.

Rahul has a BTech in Aerospace Engineering (1998) from the Indian Institute of Technology, Mumbai and an MS in Aerospace and Engineering Mechanics ( 2001) from the University of Florida.


     
Rahul Saini
     
Gerhard Maale M.D.
Dr. Gerhard Maale is the medical director of orthopedic oncology and leads the Complex Joints and Musculoskeletal Tumors Program at the Dallas Forth Worth Sarcoma Group. He has more than 35 years of experience performing complex joint reconstructions and treating bone and soft tissue disorders, bone disease, and musculoskeletal infections. After graduating from the University of Florida School of Medicine, he completed his orthopedic surgery residency at the University of Virginia and an orthopedic oncology fellowship at the University of Florida. Dr. Maale has also published work in international journals has six issued US patents and 7 patents pending.

Dr. Maale is the Founder of Dallas Ft. Worth Sarcoma Group, the Director of Orthopedic Oncology, Medical City Plano, Texas, and the Director of Sara Canon Initiative for Sarcoma HCA Hospitals. He previous posiitons include: Associate Professor, Department of Orthopedic Surgery, Texas Tech University School of Medicine, Associate Professor, Department of Pathology, Texas Tech University School of Medicine, Director, Orthopedic Oncology Fellowship, University of Texas Southwestern Medical School, Dallas, Texas, and President, Dallas/Fort Worth Texas branch of Western Orthopedic Association, His many honors include: Recipient of the Journal of Trauma Residents' Award for the Northeast Regional Competition for NIH and NCI sponsored for Oncology Fellowship, Recipient of the State of Texas House of Representatives Certificate of Appreciation for Outstanding Contributions to the Fight Against Cancer, Teaching Excellence Award-Southwestern Orthopedic Residents, and Texas Tech health Science Center, El Paso, Texas Certificate of Appreciation.


John, Chief Strategy Officer of RMD, joined Zyvex Labs in March, 2001. Prior to Zyvex, John spent 15 years with Texas Instruments (TI) where he worked in high resolution processing for integrated circuits, MEMS, and quantum effect devices and also worked at MIT's Lincoln Laboratory on ion beam and x-ray lithography. John is Executive VP at NanoRetina and currently lends his 30+ years of experience in micro- and nano-fabrication to his roles as Adjunct Professor at UT Dallas and Fellow of the AVS, IEEE, and Micro Nano Engineering Society. He has attracted over $43M in research contracts to Zyvex and resulting products have grossed over $80M. John has 114 published articles, more than 50 conference proceedings and other publications (>4200 citations) and 32 issued US Patents (>800 citations).

John has a B.S. (1975), M.S. (1977), PhD (1981) in Electrical Engineering from the University of Houston.


     
John Randall

Rapid Molecular Diagnostics LLC

1301 North Plano Road
Richardson, Texas, 75081

Contact us at: info@rapidmoleculardiagnostics.com

Contact Matthew Maale directly at: mmaale@rapidmoleculardiagnostics.com

Back to Top